Novadip Biosciences S. A., a biotech company focused on the development of novel stem cell-based therapies for regenerative medicine and IAG, Image Analysis Group, a strategic bio-pharma imaging expert announce a strategic alliance in the development of Novadip’s lead autologous stem cell therapy, NVD-003.
Novadip’s NVD-003 is a second-generation therapy improving bone healing in severe pathophysiological conditions including hypoxia, lack of mineralized callus formation, bone resorption and low osteogenicity. NVD-003 therapy supports the reconstruction and remodelling of large bone defects as may be found in different osseous non-union indications. To assess its safety and efficacy, CT and X-Ray images will be used.
IAG’s team have significant experience in using medical imaging to support drug development.
This partnership aims to design and validate imaging-based system for the assessment of radiological signs of bone formation in Congenital Pseudoarthrosis of the Tibia (CPT), a rare paediatric orthopaedic condition, and other non-union indications. The partner aim to bring a robust and validated system to support future development of NVD003 in application to CPT and other musculoskeletal conditions.
‘Unique mechanism of action of NVD003 and patient healing process will be assessed using computer added radiological review of the imaging scans. Since CPT is a rare condition, we need to ensure that treatment response is assessed comprehensively and accurately. We are pleased to have on-board world-class imaging experts, who bring their expertise to maximise NVD-003’ success in the clinic and help finding a solution for CPT patients.’ said Dr. Olga Kubassova, IAG’s CEO.
‘Novadip’s unique “3M3″ tissue regeneration technology platform, utilizing adipose-derived stem cells within a 3D extracellular matrix, is designed to transform the lives of patients with limited or no effective treatment options. This partnership will allow us comprehensively explore NVD–003 efficacy and build solid scientific data while reducing the development costs, timelines and uncertainties.’ added Dr. Denis Dufrane, the founder and CEO of Novadip.
About NVD-003: NVD-003 is an autologous stem cell therapy sourced from the stromal fraction of the patient’s adipose tissue. This 3-dimensional, malleable product is implanted at the non-union fracture site. The delivery of differentiated stem cells within their extracellular matrix in fractured pseudoarthrosis lesion(s) supplies factors and signalling molecules that can promote osteogenesis while providing appropriate mechanical stability, therefore providing the right milieu for tissue regeneration of large bone defects.
About Novadip: Novadip is a Belgian biotech company founded in 2013, based on the scientific discoveries of Prof. Denis Dufrane, Novadip’s acting CEO and CSO. The company focuses on tackling unmet medical needs using their tissue regeneration technology platform, “3M3”. Multiple product candidates, targeting different organs, arose from this platform including autologous, allogenic and miRNA / exosome-based therapies. Novadip possesses a promising pipeline tackling systemic and localised tissue defects by overcoming tissue reconstruction challenges.
About IAG: IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com
For more information, please reach to <firstname.lastname@example.org>